난소암 · FRα

155개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved155 programs
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Newly matched donor-derived CD5 CAR T-cells (Newly matched donor-derived CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Newly matched donor-derived FL-33 CAR T therapy (Newly matched donor-derived FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

ONC-PluReceptor NK cells (ONC-PluReceptor NK cells)

Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#FollicularLymphoma+2
Trials 1Status Recruiting
CGTLimited DatastalePrecision BioSciences, Inc.Phase 2

PBCAR20A (PBCAR20A)

Non-Hodgkin's Lymphoma, Relapsed; Chronic Lymphoid Leukemia in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastalePrecision BioSciences, Inc.Phase 1

PBCAR269A (PBCAR269A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleStephan Grupp MD PhDPhase 1

PHOX2B PC-CAR T Cells (PHOX2B PC-CAR T Cells)

Refractory Neuroblastoma; Relapsed Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePrecigen, IncPhase 1

PRGN-3005 UltraCAR-T cells (PRGN-3005 UltraCAR-T cells)

Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleSCRI Development Innovations, L…Phase 1

PTK787/ZK222584 and Bevacizumab (PTK787/ZK222584 and Bevacizumab)

Refractory Malignancy; Advanced Malignancies · FRα

#FR#Antibody#Phase1#monoclonal-antibody#RefractoryMalignancy+2
Trials 1Status Active
CGTLimited DatastaleMustang BioPreclinical

Prior MB-102 CAR-T cell investigational product. (Prior MB-102 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleMustang BioPreclinical

Prior MB-106 CAR-T cell investigational product. (Prior MB-106 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Prior-HSCT donor-derived CD7 CAR T-cell (Prior-HSCT donor-derived CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 2

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryMultipleMyel+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedRefractoryMultipleMyelom+1
Trials 1Status Recruiting
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

ROR1 CAR-specific Autologous T-Lymphocytes (ROR1 CAR-specific Autologous T-Lymphocytes)

Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
AntibodyLimited DatastaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NSCLC+2
Trials 1Status Recruiting
CGTLimited DatastaleSeattle Children's HospitalPhase 1

SC-CAR4BRAIN (SC-CAR4BRAIN)

Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting B7-H3 chimeric antigen receptor (T cell injection targeting B7-H3 chimeric antigen receptor)

B7-H3-positive Relapsed/ Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting FLT3 chimeric antigen receptor (T cell injection targeting FLT3 chimeric antigen receptor)

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting

7 / 8 pages

← PreviousNext →